Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
8.20
+0.22 (2.76%)
Feb 21, 2025, 5:29 PM CET
-41.47%
Market Cap 1.92B
Revenue (ttm) 104.24M
Net Income (ttm) -196.45M
Shares Out 234.58M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 995,049
Average Volume 427,432
Open 7.87
Previous Close 7.98
Day's Range 7.99 - 8.35
52-Week Range 6.92 - 24.10
Beta 0.65
RSI 44.97
Earnings Date Feb 27, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 24
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.